Haploidentical Bone Marrow Transplantation with Posttransplant Cyclophosphamide As a Curative Alternative to Matched Sibling Donor Transplantation in Pediatric Patients with Severe Aplastic Anemia

Key Points

• Haploidentical transplantation with posttransplant cyclophosphamide shows improved outcomes.
• In a cohort of pediatric patients, survival rates reflect competitive success against matched sibling donor transplants.
• Assessment of performance utilized clinical outcomes from patient records and treatment responses.
• This approach emphasizes the need for wider acceptance of alternative donor strategies in pediatric cases.